Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence
· Business · Bloomberg, Reuters, NBC News
A personalized mRNA vaccine developed by Moderna and Merck has demonstrated success in a late-stage clinical trial for melanoma. The treatment significantly reduced the risk of recurrence or death in patients diagnosed with the deadliest form of skin cancer. By tailoring the vaccine to the specific genetic profile of a patient's tumor, the therapy aims to prime the immune system to identify and destroy remaining cancer cells. This trial represents a major milestone in the application of mRNA technology beyond infectious diseases. Further regulatory assessments are expected to follow as the companies evaluate the data for potential market approval.
Why it matters
This breakthrough offers a potential new treatment pathway for high-risk melanoma patients, marking a significant shift in how personalized cancer immunotherapies are developed.
Read the original report — Bloomberg
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.